Glenmark Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals has informed the stock exchanges that its Board of Directors will meet on Friday, November 14, 2025, to consider and approve the Unaudited Financial Results for the second quarter and half year ended September 30, 2025. In line with SEBI's Prohibition of Insider Trading Regulations, the company has closed its trading window for directors and designated persons from September 30, 2025 to November 16, 2025 (both days inclusive). The window closure covers the period during which results are being finalised and approved.
This is a routine regulatory filing ahead of the Q2 FY26 earnings announcement. Investors can expect the unaudited results to be published around November 14, 2025, which is the key near-term catalyst for the stock.